Association between Comorbidities and Mortality with Survival Analysis in Stage IV Breast Cancer Patients at Dr. Soetomo General Hospital

Authors

DOI:

https://doi.org/10.36452/jmedscientiae.v5i1.4158

Keywords:

breast cancer, CCI score, comorbidity, mortality, survival analysis

Abstract

Breast cancer is a major global health concern, having the highest prevalence and ranking fifth in cancer-related mortality worldwide. However, data regarding mortality among breast cancer patients with and without comorbidities remain limited. Therefore, this study aimed to determine the association between comorbidities and mortality, as well as to analyze the survival of stage IV breast cancer patients at Dr. Soetomo General Hospital during the period 2020–2022. This study employed an observational analysis with a retrospective case–control design. Bivariate statistical analyses were performed using the Chi-square test, Fisher’s exact test, and the Mann–Whitney U test. Survival analysis was performed using the Kaplan–Meier method and the log-rank test. There were 271 samples that met the inclusion criteria. The majority of patients were early elderly (46–55 years old) and female. Based on the Charlson Comorbidity Index (CCI), most patients had severe comorbidities with a CCI score ≥ 5 (65,7%), and 48,3% of patients experienced mortality. The results showed a significant association between comorbidities and mortality in stage IV breast cancer patients (ρ = 0,00), with survival probability decreasing over time (ρ = 0,00). Patients without comorbidities had a higher probability of survival compared to those with comorbidities.

Author Biography

Abdul Khairul Rizki Purba, Department of Pharmacology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.

Abdul Khairul Rizki Purba obtained his Medical Doctor in 2007 from the Faculty of Medicine, Universitas Airlangga. In 2010, he started his Master's degree at Universitas Gadjah Mada and finished it with cumlaude predicate with research in drug-drug interactions in cancer. In 2012, he started his medical specialization in clinical pharmacology at Universitas Indonesia with an internship program at Cipto Mangunkusomo Hospital. In 2016, he conducted his Ph.D. at UMCG, University of Groningen, the Netherlands. His Ph.D. research focused on pharmacotherapy, pharmacoepidemiology, and pharmacoeconomics of antibiotic treatments. The research was conducted under Groningen University Institute for Drug Exploration. After finalizing his Ph.D., he continues working as a lecturer and researcher at the Faculty of Medicine, Universitas Airlangga. Also, he has been involved in the Drug and Therapeutics Committee and Health Technology Assessment (HTA) at Dr. Soetomo Hospital and Universitas Airlangga Hospital, Surabaya. Notably, he is an active member and committee in the national organizations of the Indonesian Medical Doctor Association, the Indonesian Pharmacology Association, and the Indonesian Clinical Pharmacology Association.

Published

2026-04-30

How to Cite

Cahyani, M. B. S., Purba, A. K. R., Wihandono, A., & Purwaningsih, S. (2026). Association between Comorbidities and Mortality with Survival Analysis in Stage IV Breast Cancer Patients at Dr. Soetomo General Hospital. Jurnal MedScientiae, 5(1). https://doi.org/10.36452/jmedscientiae.v5i1.4158

Issue

Section

Research Article